TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups LEUKEMIA Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., Haferlach, T., Kern, W., Ogawa, S., Nagata, Y., Yoshida, K., Graubert, T. A., Walter, M. J., List, A. F., Komrokji, R. S., Padron, E., Sallman, D., Papaemmanuil, E., Campbell, P. J., Savona, M. R., Seegmiller, A., Ades, L., Fenaux, P., Shih, L., Bowen, D., Groves, M. J., Tauro, S., Fontenay, M., Kosmider, O., Bar-Natan, M., Steensma, D., Stone, R., Heuser, M., Thol, F., Cazzola, M., Malcovati, L., Karsan, A., Ganster, C., Hellstrom-Lindberg, E., Boultwood, J., Pellagatti, A., Santini, V., Quek, L., Vyas, P., Tuechler, H., Greenberg, P. L., Bejar, R., Int Working Grp MDS Mol Progno 2019; 33 (7): 1747–58

View details for DOI 10.1038/s41375-018-0351-2

View details for Web of Science ID 000473724900017